Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin

References

• Eaton BR, Schwarz R, Vatner R, et al. Osteosarcoma. Pediatr Blood Cancer. 2021;68(Suppl. 2):e28352.
   PubMedGoogle Scholar
• Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–3035.
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang J, Li Y. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Front Immunol. 2022;13:871076.
   PubMed Web of Science ®Google Scholar
• Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. IJMS. 2020;21(18):6885.
   Google Scholar
• Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27(50):6398–6406.
   PubMed Web of Science ®Google Scholar
• Perini GF, Ribeiro GN, Pinto Neto JV, et al. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11(1):65.
   PubMedGoogle Scholar
• Townsend PA, Kozhevnikova MV, Cexus ONF, et al. BH3-mimetics: recent developments in cancer therapy. J Exp Clin Cancer Res. 2021;40(1):355.
   PubMed Web of Science ®Google Scholar
• Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7(12):989–1000.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukaemia and related B cell malignancies. Clin Pharmacol Ther. 2017;101(1):89–98.
   PubMed Web of Science ®Google Scholar
• Samra B, Konopleva M, Isidori A, et al. Venetoclax-Based combinations in acute myeloid leukaemia: current evidence and future directions. Front Oncol. 2020;10:562558.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.
   PubMed Web of Science ®Google Scholar
• Maji S, Panda S, Samal SK, et al. Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 2018;137:37–75.
   PubMed Web of Science ®Google Scholar
• Bauer C, Hees C, Sterzik A, et al. Proapoptotic and antiapoptotic proteins of the bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity. J Immunother. 2015;38(3):116–126.
   PubMed Web of Science ®Google Scholar
• Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11(7):556.
   PubMed Web of Science ®Google Scholar
• Yadav B, Wennerberg K, Aittokallio T, et al. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504–513.
   PubMed Web of Science ®Google Scholar
• Cao C, Yu H, Wu F, et al. Antibiotic anisomycin induces cell cycle arrest and apoptosis through inhibiting mitochondrial biogenesis in osteosarcoma. J Bioenerg Biomembr. 2017;49(6):437–443.
   PubMed Web of Science ®Google Scholar
• Satta T, Grant S. Enhancing venetoclax activity in hematological malignancies. Expert Opin Investig Drugs. 2020;29(7):697–708.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Yu D, Zhang S, Feng A, et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: a meta-analysis and clinical observation. Medicine (Baltimore). 2019;98(19):e15582.
   PubMed Web of Science ®Google Scholar
• Garcia-Ortega DY, Cabrera-Nieto SA, Caro-Sanchez HS, et al. An overview of resistance to chemotherapy in osteosarcoma and future perspectives. Cancer Drug Resist. 2022;5(3):762–793.
   PubMedGoogle Scholar
• Geng M, Wang L, Li P. Correlation between chemosensitivity to anticancer drugs and bcl-2 expression in gastric cancer. Int J Clin Exp Pathol. 2013;6(11):2554–2559.
   PubMed Web of Science ®Google Scholar
• Williams J, Lucas PC, Griffith KA, et al. Expression of bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 2005;96(2):287–295.
   PubMed Web of Science ®Google Scholar
• Jia Y, Han L, Ramage CL, et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukaemia cells and enhances efficacy of chemotherapy by targeting senescent cells. haematol. 2023;
   PubMedGoogle Scholar
• Kontos CK, Christodoulou MI, Scorilas A. Apoptosis-related BCL2-family members: key players in chemotherapy. Anticancer Agents Med Chem. 2014;14(3):353–374.
   PubMed Web of Science ®Google Scholar
• Fu T, Xia C, Li Z, et al. Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysis. Int J Clin Exp Med. 2015;8(6):9093–9099.
   PubMed Web of Science ®Google Scholar
• Giacomini I, Cortini M, Tinazzi M, et al. Contribution of mitochondrial activity to doxorubicin-resistance in osteosarcoma cells. Cancers (Basel). 2023;15(5):1370.
   PubMed Web of Science ®Google Scholar
• Belisario DC, Akman M, Godel M, et al. ABCA1/ABCB1 ratio determines chemo- and immune-sensitivity in human osteosarcoma. Cells. 2020;9(3):647.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumours. J Clin Oncol. 2011;29(7):909–916.
   PubMed Web of Science ®Google Scholar
• Joly F, Fabbro M, Follana P, et al. A phase II study of navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: the MONAVI – GINECO study. Gynecol Oncol. 2022;165(1):30–39.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18(11):3163–3169.
   PubMed Web of Science ®Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149–1159.
   PubMed Web of Science ®Google Scholar